CR10638A - Uso de derivados de azibiciclo hexano - Google Patents

Uso de derivados de azibiciclo hexano

Info

Publication number
CR10638A
CR10638A CR10638A CR10638A CR10638A CR 10638 A CR10638 A CR 10638A CR 10638 A CR10638 A CR 10638A CR 10638 A CR10638 A CR 10638A CR 10638 A CR10638 A CR 10638A
Authority
CR
Costa Rica
Prior art keywords
azibiciclo
hexan
derivatives
methyl
oxaxol
Prior art date
Application number
CR10638A
Other languages
English (en)
Spanish (es)
Inventor
Clare Louise Anderton
Sergio Bacchi
Stefania Beato
Franco Sartor
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37081324&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10638(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2006/008314 external-priority patent/WO2007022980A1/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CR10638A publication Critical patent/CR10638A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CR10638A 2006-08-21 2009-02-25 Uso de derivados de azibiciclo hexano CR10638A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2006/008314 WO2007022980A1 (en) 2005-08-22 2006-08-21 Use of azabicyclo hexane derivatives
GBGB0616574.0A GB0616574D0 (en) 2006-08-21 2006-08-21 Compounds

Publications (1)

Publication Number Publication Date
CR10638A true CR10638A (es) 2009-03-20

Family

ID=37081324

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10638A CR10638A (es) 2006-08-21 2009-02-25 Uso de derivados de azibiciclo hexano

Country Status (22)

Country Link
US (1) US20080058398A1 (cg-RX-API-DMAC7.html)
EP (1) EP2054054A1 (cg-RX-API-DMAC7.html)
JP (1) JP5315244B2 (cg-RX-API-DMAC7.html)
KR (1) KR101495362B1 (cg-RX-API-DMAC7.html)
CN (1) CN101528221B (cg-RX-API-DMAC7.html)
AR (1) AR062471A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007287527B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0716454A2 (cg-RX-API-DMAC7.html)
CA (1) CA2661437A1 (cg-RX-API-DMAC7.html)
CL (1) CL2007002422A1 (cg-RX-API-DMAC7.html)
CO (1) CO6150139A2 (cg-RX-API-DMAC7.html)
CR (1) CR10638A (cg-RX-API-DMAC7.html)
EA (1) EA017917B1 (cg-RX-API-DMAC7.html)
GB (1) GB0616574D0 (cg-RX-API-DMAC7.html)
IL (1) IL196976A0 (cg-RX-API-DMAC7.html)
MA (1) MA30672B1 (cg-RX-API-DMAC7.html)
MX (1) MX2009001941A (cg-RX-API-DMAC7.html)
NO (1) NO20090834L (cg-RX-API-DMAC7.html)
PE (1) PE20080609A1 (cg-RX-API-DMAC7.html)
TW (1) TW200825074A (cg-RX-API-DMAC7.html)
WO (1) WO2008022994A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200900886B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101143718B1 (ko) * 2004-02-23 2012-07-05 글락소 그룹 리미티드 도파민 ｄ3 수용체의 조절제로서 유용한 아자비시클로(3.1.0) 헥산 유도체
GB0507602D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507601D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0512099D0 (en) * 2005-06-14 2005-07-20 Glaxo Group Ltd Compounds
JP5068747B2 (ja) * 2005-06-14 2012-11-07 グラクソ グループ リミテッド ドーパミンｄ３受容体のモジュレーターとしてのアザビシクロ［３．１．０］ヘキサン誘導体
GB0517187D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
ATE487715T1 (de) * 2005-08-22 2010-11-15 Glaxo Group Ltd Triazolderivate als modulatoren von dopamin-d3- rezeptoren
GB0517191D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517175D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517193D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use
WO2007113260A1 (en) * 2006-04-03 2007-10-11 Glaxo Group Limited Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors
EP2010518B1 (en) * 2006-04-03 2011-02-16 Glaxo Group Limited Azabicyclo [3. 1. o] hexane derivatives as modulators of dopamine d3 receptors
WO2008153937A2 (en) * 2007-06-06 2008-12-18 Dov Pharmaceutical, Inc. Novel 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
WO2019146740A1 (ja) 2018-01-26 2019-08-01 塩野義製薬株式会社 ドーパミンｄ３受容体拮抗作用を有する環式化合物
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
AR127055A1 (es) 2021-09-14 2023-12-13 Lilly Co Eli Sales agonistas de sstr4

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4260941B2 (ja) * 1998-11-09 2009-04-30 株式会社片山製薬所 アゼチジン−３−オール
EP1163217B1 (en) * 1999-03-15 2005-09-21 Novo Nordisk A/S New salt of (2r,3r,4r)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
GB0019228D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
KR101143718B1 (ko) * 2004-02-23 2012-07-05 글락소 그룹 리미티드 도파민 ｄ3 수용체의 조절제로서 유용한 아자비시클로(3.1.0) 헥산 유도체
SE526837C2 (sv) * 2004-02-24 2005-11-08 Kongsberg Automotive Asa Växelspakstransmission
AU2005267579A1 (en) * 2004-06-30 2006-02-02 Eli Lilly And Company 1 (indole-6-carbonyl-D-phenylglycinyl) -4- (1-methylpiperidin-4-yl) piperazine D-tartrate
GB0517193D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use

Also Published As

Publication number Publication date
EA200970211A1 (ru) 2009-08-28
AU2007287527A1 (en) 2008-02-28
MX2009001941A (es) 2009-03-05
KR101495362B1 (ko) 2015-02-24
GB0616574D0 (en) 2006-09-27
TW200825074A (en) 2008-06-16
CO6150139A2 (es) 2010-04-20
AR062471A1 (es) 2008-11-12
BRPI0716454A2 (pt) 2014-03-04
ZA200900886B (en) 2011-05-25
NO20090834L (no) 2009-03-19
WO2008022994A1 (en) 2008-02-28
US20080058398A1 (en) 2008-03-06
EA017917B1 (ru) 2013-04-30
CN101528221A (zh) 2009-09-09
CA2661437A1 (en) 2008-02-28
MA30672B1 (fr) 2009-08-03
AU2007287527B2 (en) 2013-01-31
EP2054054A1 (en) 2009-05-06
CN101528221B (zh) 2013-05-08
CL2007002422A1 (es) 2008-03-14
PE20080609A1 (es) 2008-07-26
IL196976A0 (en) 2009-11-18
JP5315244B2 (ja) 2013-10-16
KR20090052327A (ko) 2009-05-25
JP2010501519A (ja) 2010-01-21

Similar Documents

Publication Publication Date Title
CR10638A (es) Uso de derivados de azibiciclo hexano
EA201000702A1 (ru) Некоторые производные 2-пиразинона и их применение в качестве ингибиторов нейтрофильной эластазы
EA201000486A1 (ru) Ингибитор белка, активирующего 5-липоксигеназу (flap)
UY32461A (es) Sal de tosilato de 6-metil-5-(metil-1h-pirazol-5-il)-n-{[e-(metilsulfonil)piridin-2-il]metil -2-oxo-1-[3-(trifluorometil)fenil]-1,2-dihidropiridin-3-carboxamida
ECSP10010265A (es) Sales farmaceuticamente aceptables de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8 dihidro-9h-purin-9-il)propil](3-morfolin-4 ilpropil)amino]metil}fenil)
LT3184523T (lt) N-((4,6-dimetil-2-okso-1,2-dihidropiridin-3-il)metil)-5-(etil (tetrahidro-2h-piran-4-il)amino)-4-metil-4'-(morfolinometil)-[1,1'-bifenil]-3-karboksamido hidrobromidas, skirtas naudoti hematologinės sistemos proliferacinio sutrikimo gydymui
NI201200072A (es) Métodos y composiciones para tratar cáncer
ZA200710513B (en) Control of parasites in animals by N-[(phenyloxy)phenyl]-1,1,1-trifluoromethanesulfonamide and N-[(phenylsulfanyl)-phenyl]-1, 1, 1-trifluoromethanesulfonamide derivatives
TW200745099A (en) Optically active thiazolidinedione derivatives
SV2005002148A (es) "compuestos moduladores de la actividad c-kit y usos de los mismos"
NO20091413L (no) WNT-antagonister og deres anvendelse i diagnostiseringen og behandlingen av WNT-medierte forstyrrelser
AR067540A1 (es) Compuesto de aril (isoxazol-4-il-metoxilo) , su uso para preparar un medicamento y composicion farmaceutica que lo comprende
BRPI0814267A2 (pt) Agentes citotóxicos compreendendo novos derivados de tomaicmicina e o seu uso terapêutico.
BR112014003237A2 (pt) compostos de indazol, composições e métodos de uso
CL2007001427A1 (es) Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po
BRPI0607545A2 (pt) composto, uso de um composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
UA112055C2 (uk) Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну
SG164283A1 (en) New benzimidazole derivatives
BRPI0615898B8 (pt) composição farmacêutica, e, uso de um composto ou de um sal, um solvato, um hidrato ou uma forma morfológica do mesmo farmaceuticamente aceitável
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
MA35716B1 (fr) Formulations pharmaceutiques
CL2007001692A1 (es) Sal de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida; composicion farmaceutica, util para tratar una enfermedad que responde a una inhibicion de la actividad de cinasa de proteina.
UA107353C2 (en) Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof
EA200800542A1 (ru) Пиридинаминосульфонилзамещенные бензамиды в качестве ингибиторов цитохрома р450 3а4 (cyp3a4)
PL1771069T3 (pl) Pochodne N-(2-(hydroksymetylo)fenylo)-1H-pirazolo-4-karboksamidu i związki pokrewne jako mikrobójcze substancje czynne do zastosowania w ochronie roślin i materiałów

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)